HCM
GNCA

Highbridge Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Highbridge Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,252
Closed -$124K – 1963
2015
Q3 		$124K Buy
+2,252
New +$223K ﹤0.01% 1422

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Highbridge Capital Management's GNCA Position: Q4 2015 in Review

Highbridge Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2015, closing a stake of 2,252 shares — an estimated $124K sold.

Highbridge Capital Management first reported a position in GNCA in Q3 2015 and held it in 1 quarter. The position peaked at $124K in Q3 2015. 57 funds tracked by Wall St. Rank hold GNCA as of Q4 2015.

  • Highbridge Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q4 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 2,252 Genocea Biosciences, Inc. shares in Q4 2015, an estimated $124K.
  • Highbridge Capital Management first reported a position in Genocea Biosciences, Inc. in Q3 2015 and held it in 1 quarter.
  • Highbridge Capital Management's Genocea Biosciences, Inc. position peaked at $124K in Q3 2015.
  • 57 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2015.

Based on Highbridge Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.